CEO received an award of 89K BMRN derivative securities | OQRO Insider tradesWhy it stands out
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Mar 16, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Mar 18, 2026
CEOGrant / award
Context
- Classification
grant award
Code A — grant or award
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001628280-26-019006
- Filed / recorded
Mar 18, 2026, 12:43 AM UTCAdded to OQROOct 6, 2026, 4:40 PM UTC Data qualityVerified: identifiers matched exactly IssuerBIOMARIN PHARMACEUTICAL INC Reporting personAlexander Hardy RelationshipDirector, Officer Officer titleChief Executive Officer SecurityStock Option (Right to Buy Common Stock) TableDerivative (Table II) Transaction dateMar 16, 2026 Acquired / disposedAcquired (A) Footnotes from the filing
- Option grant vests 12/48th on March 16, 2027 and 1/48th on the 16th day of each month thereafter.
Around the same time
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.
Routine share withholding; mechanical by default.